View Older Stories View More Recent Stories

Aug 30, 2021 06:31AM SpringWorks Therapeutics Inc. (SWTX) Partners with Dana-Farber Cancer Institute to Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
Aug 30, 2021 06:30AM SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
Aug 30, 2021 06:30AM SpringWorks Therapeutics Enters into Research Collaboration with Leading Cancer Institute to Further Evaluate Nirogacestat as a BCMA Potentiator in Multiple Myeloma
Aug 4, 2021 06:30AM SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Aug 4, 2021 06:30AM SpringWorks Therapeutics Reports Second Quarter 2021 Financial Results and Recent Business Highlights
Aug 3, 2021 09:00AM SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference
Aug 3, 2021 09:00AM SpringWorks Therapeutics to Present at the 12th Annual Wedbush PacGrow Healthcare Conference
Aug 3, 2021 06:30AM SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations
Aug 3, 2021 06:30AM SpringWorks Therapeutics Announces Phase 1b/2a Clinical Trial of Mirdametinib in Patients with Advanced Solid Cancers Harboring MAPK-Activating Mutations
Jul 27, 2021 08:08AM SpringWorks Therapeutics Inc. (SWTX) Appoints Dr. James Cassidy as Chief Medical Officer
Jul 27, 2021 08:00AM SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer
Jul 27, 2021 08:00AM SpringWorks Therapeutics Appoints Dr. James Cassidy as Chief Medical Officer
Jul 20, 2021 07:33AM SpringWorks Therapeutics Inc. (SWTX) Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041
Jul 20, 2021 07:30AM SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041
Jul 20, 2021 07:30AM SpringWorks Therapeutics Announces Issuance of New U.S. Composition of Matter Patent to Polymorphic Form of Mirdametinib, Extending Patent Protection Into 2041
Jun 28, 2021 07:00AM Precision BioSciences and SpringWorks Therapeutics Dose First Patient in Expanded Phase 1/2a Clinical Trial Evaluating PBCAR269A with Nirogacestat in Patients with Relapsed/Refractory Multiple Myeloma
Jun 16, 2021 06:30AM SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma
Jun 16, 2021 06:30AM SpringWorks Therapeutics Announces Initiation of Phase 1/2 Clinical Trial of Mirdametinib in Children and Young Adults with Low-Grade Glioma
Jun 15, 2021 04:05PM SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference
Jun 15, 2021 04:05PM SpringWorks Therapeutics Announces Presentation of Updated Interim Data from the Phase 2b ReNeu Trial at the 2021 Children’s Tumor Foundation NF Conference
Jun 7, 2021 06:31AM SpringWorks Therapeutics (SWTX) Announces Clinical Collaboration with Seagen (SGEN) to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with R/R Multiple Myeloma
Jun 7, 2021 06:30AM SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma
Jun 7, 2021 06:30AM SpringWorks Therapeutics Announces Clinical Collaboration with Seagen to Evaluate Nirogacestat in Combination with SEA-BCMA in Patients with Relapsed or Refractory Multiple Myeloma
Jun 1, 2021 06:30AM SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
Jun 1, 2021 06:30AM SpringWorks Therapeutics to Present at the Goldman Sachs 42nd Annual Global Healthcare Conference
May 14, 2021 06:30AM SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit
May 14, 2021 06:30AM SpringWorks Therapeutics to Present at the Cowen 2nd Annual Oncology Innovation Summit
May 10, 2021 06:30AM SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development
May 10, 2021 06:30AM SpringWorks Therapeutics Appoints Dr. Mike Burgess as Head of Research and Development
May 6, 2021 06:30AM SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 6, 2021 06:30AM SpringWorks Therapeutics Reports First Quarter 2021 Financial Results and Recent Business Highlights
May 6, 2021 06:04AM SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio
May 6, 2021 06:04AM SpringWorks Therapeutics Expands Targeted Oncology Pipeline with Exclusive Worldwide License to TEAD Inhibitor Portfolio
Apr 12, 2021 08:34AM Allogene Therapeutics (ALLO), SpringWorks Therapeutics (SWTX) Report First Patient Dosing in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with R/R Multiple Myeloma
Apr 12, 2021 08:30AM Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multip
Apr 12, 2021 08:30AM Allogene Therapeutics and SpringWorks Therapeutics Announce Dosing of First Patient in Phase 1 Study Evaluating ALLO-715 in Combination with Nirogacestat in Patients with Relapsed or Refractory Multip
Apr 1, 2021 06:32AM SpringWorks (SWTX) Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen's BCMA Bispecific Antibody Teclistamab in Patients with R/R MM
Apr 1, 2021 06:30AM SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refra
Apr 1, 2021 06:30AM SpringWorks Therapeutics Announces Dosing of First Patient in Phase 1b Combination Study Evaluating Nirogacestat and Janssen’s BCMA Bispecific Antibody Teclistamab in Patients with Relapsed or Refra
Mar 22, 2021 06:30AM SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer
Mar 22, 2021 06:30AM SpringWorks Therapeutics Appoints Bhavesh Ashar as Chief Commercial Officer
Feb 25, 2021 06:54AM SpringWorks Therapeutics Inc. (SWTX) Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update
Feb 25, 2021 06:45AM SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Feb 25, 2021 06:45AM SpringWorks Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Business Highlights
Feb 25, 2021 06:30AM SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update
Feb 25, 2021 06:30AM SpringWorks Therapeutics Reports Interim Data from Phase 2b ReNeu Trial of Mirdametinib for Patients with NF1-PN and Provides Trial Update
Feb 22, 2021 06:30AM SpringWorks Therapeutics to Present at Upcoming Investor Conferences
Feb 22, 2021 06:30AM SpringWorks Therapeutics to Present at Upcoming Investor Conferences
Feb 4, 2021 06:30AM SpringWorks Therapeutics to Present at the Guggenheim Healthcare Talks 2021 Oncology Day
Feb 4, 2021 06:30AM SpringWorks Therapeutics to Present at the Guggenheim Healthcare Talks 2021 Oncology Day
View More Recent Stories View Older Stories